VERAPAMIL ( DrugBank: Verapamil )

3 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	1
140	Dorabe syndrome	1
167	Marfan syndrome	2

96. Crohn disease

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01261286 (ClinicalTrials.gov)	August 2010	14/12/2010	Drug-Disease Interaction in Crohn's Disease	Pharmacodynamics and Pharmacokinetics of Verapamil in Crohn's Disease Patients	Crohn's Disease	Drug: verapamil	University of Alberta	NULL	Completed	18 Years	65 Years	Both		Phase 1	Canada

Clinical trials : 104 / Drugs : 61 - (DrugBank : 14) / Drug target genes : 48 - Drug target pathways : 63

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01607073 (ClinicalTrials.gov)	April 2012	24/5/2012	Verapamil as Therapy for Children and Young Adults With Dravet Syndrome	Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome	Dravet Syndrome	Drug: Verapamil	Gillette Children's Specialty Healthcare	Mayo Clinic;Ann & Robert H Lurie Children's Hospital of Chicago;Dartmouth-Hitchcock Medical Center	Completed	2 Years	25 Years	All	2	Phase 2	United States

Clinical trials : 20 / Drugs : 39 - (DrugBank : 10) / Drug target genes : 10 - Drug target pathways : 50

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01295047 (ClinicalTrials.gov)	July 2006	11/2/2011	Comparison of Medical Therapies in Marfan Syndrome.	Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular Function in Marfan Syndrome - A Randomised Double-Blind Crossover Trial	Marfan Syndrome	Drug: Atenolol;Drug: VERAPAMIL;Drug: Perindopril	Cardiff University	NULL	Completed	16 Years	60 Years	Both	18	Phase 4	United Kingdom
2	EUCTR2005-000749-13-GB (EUCTR)	30/07/2005	20/06/2005	A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome.	A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome.	Marfan Syndrome	Trade Name: Atenolol Product Name: Atenolol Product Code: N/A INN or Proposed INN: N/A Other descriptive name: N/A Trade Name: Coversyl Product Name: Coversyl Product Code: N/A INN or Proposed INN: N/A Other descriptive name: PERINDOPRIL Trade Name: Verapamil Product Name: Verapamil SR Product Code: N/A INN or Proposed INN: N/A Other descriptive name: N/A	Cardiff University	NULL	Not Recruiting			Female: yes Male: yes	60	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom